Dr Suhail Nurbhai is a highly accomplished physician-scientist, Dr Nurbhai brings deep expertise in advancing therapeutics from preclinical development through regulatory approval and into the clinic. His leadership will be instrumental as Elasmogen progresses its first-in-class drug conjugate, ELN28, into clinical trials for patients living with Hidradenitis Suppurativa.
